We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus.
- Authors
Kozich, Z.; Martinkov, V.; Pugacheva, Z.; Smirnova, L.
- Abstract
Introduction: The detection of immunophenotype of plasma cells is very important for diagnosis of multiple myeloma. Mechanism of appearing of different antigens on the surface of malignant plasma cells and their correlation with overall survival isn't sufficiently studied. Objective: To compare the overall survival and remission rates according to the expression of CD56, CD117, CD33, CD20 antigens in patients with multiple myeloma. Materials and Methods: The study included 96 patients with newly diagnosed MM at the age of 35-83 years (median - 63 years) from Gomel region of Belarus. The diagnosis was confirmed by the presence of pathological immunoglobulin in the blood and/or urine and tumor immunophenotype of the bone marrow plasma cells. By secretion variant: non-secretive, Bence-Jones, IgG, IgA at stage II, III. The results were assessed after three standard courses of VAD chemotherapy for patients <60 and VMCP courses for patients> 60years old. Antigen expression was determined by flow cytometry method. Results: Expression of CD56 was detected in 74,1% cases, CD117 in 44% cases, CD33 in 28%, CD20 in 35,3% cases. Also the presence of a soft-tissue component was more often noted in patients with increased CD20 expression. There were no statistically significant differences in the expression rate of CD56, CD117, CD33, CD20 antigens depending on the variant of multiple myeloma (non-secretive, Bence-Jones, IgG, IgA). The frequency of remission was not different depending on the presence of CD56 antigens (p=0.418), CD33 (p=0.471), CD20 (p=0.151), CD117 (p=0.689) (Fisher Exact Test). After analyzing overall survival its rate appeared to be slightly less in patients with expression of each studied antigen. The lowest overall survival was detected in patients with expression of CD56 (p=0.057 Gehan's Wilcoxon Test). Conclusion: The detection of expression of CD56, CD117, CD33, CD20 antigens can be an unfavorable prognostic factor for multiple myeloma associated with worse overall survival.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2017, Vol 17, pS19
- ISSN
2152-2650
- Publication type
Article
- DOI
10.1016/j.clml.2017.09.047